The value of platinum compounds in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue 4, 2002, Pages 249-253

  Hanna, Nasser H ^a   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Paclitaxel; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BETA TUBULIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MESSENGER RNA; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRACTICE GUIDELINE; REVIEW; STANDARDIZATION; VOMITING;

EID: 0036308506     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.008     Document Type: Review

References (36)

1. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer
2. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
3. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial
4. Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study
5. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer
6. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
7. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis
8. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
9. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
10. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology
11. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
12. Survival determinnats in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
13. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
14. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
15. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
16. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma
17. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
18. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
19. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
20. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
21. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
22. Single agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost effectiveness
23. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG)
24. Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable, advanced and metastatic non-small cell lung cancer (NSCLC)
25. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
26. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
27. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
28. Comparative analysis of different regimens of first-line chemotherapy (CT) in 784 inoperable non-small cell lung cancer (NSCLC) patients (PTS)
29. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial
30. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer
31. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non small cell lung cancer (NSCLC). A preliminary analysis
32. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer Lung Cancer Group phase III trial (GEPC/98-02)
33. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients
34. Predictive molecular markers in non-small cell lung cancer
35. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing non-small cell lung cancer (NSCLC)
36. Intermittent oral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study